



Corticosteroids in COVID-19: one size does not fit all

Athena Gogali, Chris Kyriakopoulos  and Konstantinos Kostikas 

Affiliation: Respiratory Medicine Dept, University Hospital of Ioannina, Ioannina, Greece.

Correspondence: Konstantinos Kostikas, University of Ioannina, Respiratory Medicine Dept, University Hospital of Ioannina, Leoforos Stavrou Niarchou, Ioannina 45100, Greece. E-mail: ktkostikas@gmail.com

 @ERSpublications

Organising pneumonia and acute fibrinous and organising pneumonia have been reported as the predominant patterns in pathological samples from COVID-19 patients. Critically ill COVID-19 patients may benefit even more from higher corticosteroid doses. <https://bit.ly/3timqPM>

Cite this article as: Gogali A, Kyriakopoulos C, Kostikas K. Corticosteroids in COVID-19: one size does not fit all. *Eur Respir J* 2021; 57: 2100224 [<https://doi.org/10.1183/13993003.00224-2021>].

This single-page version can be shared freely online.

To the Editor:

EDALATIFARD *et al.* [1], in a single-blind randomised controlled clinical trial, showed that methylprednisolone pulse administration (250 mg per day intravenously for 3 days) to hospitalised, not intubated patients with severe coronavirus disease 2019 (COVID-19), significantly improved survival and duration of recovery compared to standard care; the effect was more prominent in patients receiving noninvasive ventilation and reservoir mask support.